Celebrating Major Milestones in Personalized Orthopaedics, restor3d Announces First Surgery Using the Next Generation Kinos Axiom® Total Ankle System Featuring TIDAL Technology™ and Launches Mobile Companion App of r3id Personalized Surgery Platform
restor3d, a leading medical device company that develops innovative technologies and manufactures 3D printed implants and instruments, celebrates two incredible company milestones. The first being the successful implantation of the next generation Kinos Axiom® Total Ankle…
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the evaluation of lung ventilation
Polarean Imaging, a start-up founded by Dr. Bastiaan Driehuys (Radiology, SOM), has received FDA approval for its hyperpolarized xenon gas blend, trade name XENOVIEW.
Invented at Duke 2022 brings together the university research, innovation, and entrepreneurship community
Members of the Duke research, innovation, and entrepreneurship community gathered for the annual celebration of inventions and inventors, as well as to network with each other and various internal and external partners.
Tellus Therapeutics Announces $35 Million Series A Financing
Tellus Therapeutics, a neonatal care company developing treatments for newborns in the neonatal intensive care unit (NICU), announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny…
‘Pluck those diamonds’: Bayer’s Vividion eyes up to nine oncology targets from Duke spinout
After snapping up Vividion before it could jump onto Nasdaq last August, Bayer’s preclinical ‘arms-length’ subsidiary is betting on a relatively unknown North Carolina upstart in a five-year pact.
Gore acquires InnAVasc Medical, Inc., a Duke startup
Developed by Jeff Lawson, MD, PhD and Shawn Gage, PA-C in Duke University School of Medicine’s Department of Surgery, the InnAVasc device is specifically designed to allow for safe, easy, reproduceable and durable access for…
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Radius first licensed the indication for this drug discovered out of the Donald McDonnell lab from Duke in 2017.
Evecxia Therapeutics Announces Leadership Transition to Support Next Phase of Development and Growth
Joseph M. Patti, Ph.D., Appointed President and CEO John J. Kaiser, Retires as CEO, Remains as Board Director RESEARCH TRIANGLE PARK, N.C., June 13, 2022–(BUSINESS WIRE)–Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing…
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
ALBANY, N.Y.,June 9, 2022–(BUSINESS WIRE)–Curia, formerly AMRI, a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer and to treat autoimmune and inflammatory disorders…